Spinal Cord Stimulation News and Research

RSS

Medtronic launches Defeat-HF clinical trial to evaluate SCS for heart failure

Medtronic, Inc. today announced the global launch of the Defeat-HF (Determining the Feasibility of Spinal Cord Neuromodulation for the Treatment of Chronic Heart Failure) clinical trial. It is the industry's first prospective, randomized study evaluating the clinical feasibility of spinal cord stimulation, or neurostimulation, to improve clinical signs and symptoms of heart failure.

30 Jul 2010

Boston Scientific launches SCS lead splitters for use with Precision Plus Spinal Cord Stimulator System

Boston Scientific Corporation today announced U.S. Food and Drug Administration approval and launch of two spinal cord stimulation (SCS) lead splitters for use with its Precision Plus™ Spinal Cord Stimulator System, the world's first rechargeable SCS device for the management of chronic pain of the trunk, back and/or limbs.

24 Jun 2010

SCS may be able to modulate PD symptoms: Study

A new study from Rhode Island Hospital indicates that spinal cord stimulation may be able to modulate Parkinson's disease symptoms. The lead author will present the findings at the 2010 American Society for Stereotactical and Functional Neurosurgery Biennial Meeting, June 14-16 in New York City.

15 Jun 2010

St. Jude Medical's Epiducer lead delivery system for neurostimulation therapy receives CE Mark approval

St. Jude Medical, Inc., a global medical device company, today announced European CE Mark approval of its new Epiducer™ lead delivery system for neurostimulation therapy. Unveiled at the Neurosurgery 2010 Congress in Lyon, France, the Epiducer lead delivery system is the first of its kind, allowing introduction of S-Series perc-paddle leads as well as multiple lead arrays through a single percutaneous entry point.

27 May 2010

Boston Scientific commences enrollment in trial comparing SCS to spine reoperation in FBSS patients

Boston Scientific Corporation today announced the start of patient enrollment in the EVIDENCE Clinical Trial, which compares the therapeutic effectiveness and cost effectiveness of spinal cord stimulation (SCS) therapy to spine reoperation in patients with failed back surgery syndrome (FBSS). The first patient was enrolled by Joseph Buwembo, M.D. and Krishna Kumar, M.D., F.R.C.S.C., at Regina General Hospital in Regina, Saskatchewan, Canada.

4 May 2010

Hope for back pain: Minimally invasive facet arthrodesis and spinal cord stimulation

Results from the first prospective study of minimally invasive facet arthrodesis and long-term data on spinal cord stimulation demonstrate the viability of these options to achieve pain relief in patients with various back pain conditions. The studies were presented today at the American Academy of Pain Medicine's 26th Annual Meeting in San Antonio, TX.

5 Feb 2010

Peripheral nerve stimulation promising for treatment of post-herpetic neuralgia

Doctors from the Mayo Clinic in Jacksonville, Florida showcased positive results of peripheral nerve stimulation (PNS) in a patient suffering from post-herpetic neuralgia (PHN), or pain after a herpes breakout.

4 Feb 2010

Electrode devices emerge as potential stimulation treatments for depression

Approximately ten to thirty percent of patients with depression do not respond to drug treatments commonly used for the disorder, and this has spurred a search for alternatives. According to Kalorama Information's report "Electrical and Magnetic Neurostimulation," electrode devices that stimulate nerves have emerged as a solution and there is competition among notable device companies to provide the most effective stimulator.

28 Jan 2010

Japanese MHLW approves St. Jude Medical's Genesis spinal cord stimulation system

St. Jude Medical, Inc. today announced regulatory approval from the Japanese Ministry of Health, Labor and Welfare (MHLW) for the Genesis™ spinal cord stimulation system for the management of chronic pain.

18 Jan 2010

St. Jude Medical announces implantation of the first patient in China with its Eon rechargeable neurostimulator

St. Jude Medical, Inc. announced today that a 62-year-old man from Shenzhen, Guangdong province has become the first patient in China to be implanted with the Eon™ neurostimulator, a rechargeable device used to help manage chronic pain. Despite prior back surgeries, the patient suffered from chronic back pain for more than a decade.

18 Nov 2009

Spinal Modulation completes its $27.4 million Series C financing

Spinal Modulation, Inc. announced today the completion of its $27.4 million Series C financing. Johnson & Johnson Development Corporation (JJDC) joined existing major investors including DeNovo Ventures, ePlanet/DFJ, Kleiner Perkins Caufield & Byers, and MedVenture Associates in this financing. DFJ/InCube Ventures and Raffles Venture Partners are additional new investors.

4 Nov 2009

Study reveals that increased neurostimulation market offers growth for device industries

The device industry would do well to focus on the treatment needs of individuals suffering from nerve-related disorders as implanted technologies that deliver electrical stimulation begin to supplant drugs for treating certain nerve-related disorders.

24 Aug 2009

Dollar-sized medical device provides injured military skydiver with pain relief

St. Jude Medical, Inc. today announced the first patient implant of an Eon Mini, the world's smallest, longest-lasting, rechargeable neurostimulator to treat chronic pain of the trunk or limbs and pain from failed back surgery.

17 Sep 2008

St. Jude Medical receives approval of first extended-life primary cell neurostimulator for treatment of chronic pain

St. Jude Medical, Inc. has announced U.S. Food and Drug Administration (FDA) and European CE Mark approvals of EonC, the first extended-life primary cell (non-rechargeable) neurostimulator for the treatment of chronic pain.

13 Aug 2008

New ANS spinal cord stimulation lead for patients with low back pain

St. Jude Medical, Inc. has announced U.S. Food and Drug Administration (FDA) clearance of two spinal cord stimulation tripolar paddle leads for use with the Renew Neurostimulation System.

15 Feb 2007

Advanced Neuromodulation Systems receives European approval for Rapid Programmer

Advanced Neuromodulation Systems (ANS), the neuromodulation business of St. Jude Medical, Inc., has announced European CE Mark approval for its newest clinician programming platform, Rapid Programmer 3.0 for spinal cord stimulation (SCS), an advanced therapy for managing chronic pain.

18 Jan 2007

Advanced Neuromodulation Systems receives Australian approval for rechargeable chronic pain system

Advanced Neuromodulation Systems (ANS), the neuromodulation business of St. Jude Medical, Inc, today announced Australian Therapeutic Goods Administration (TGA) regulatory approval for its Eon Rechargeable Neurostimulation System.

3 Oct 2006

Assessment of spinal cord stimulator in treatment of chronic pain

A neurosurgeon at the University of Illinois at Chicago is assessing how well an implanted electronic device that stimulates nerve fibers in the spinal cord relieves chronic pain.

7 Jun 2004